Fig. 2From: Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancersCancer outcomes in the dose escalation cohort of the PEMBIB trial: waterfall plot (A), spider plot (B) and swimmer plot (C)Back to article page